PMID- 28399526
OWN - NLM
STAT- MEDLINE
DCOM- 20180122
LR  - 20220321
IS  - 1423-0291 (Electronic)
IS  - 1015-2008 (Linking)
VI  - 84
IP  - 4
DP  - 2017
TI  - Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer.
PG  - 210-217
LID - 10.1159/000464250 [doi]
AB  - OBJECTIVE: Gastric cancer (GC) is the second most common cancer and the third 
      leading cause of cancer-related death in Korea. Alterations in the ERBB (homology 
      to the erythroblastoma viral gene product, v-erbB) receptor family and 
      ERBB-related signaling pathways are frequently observed in GC. However, the roles 
      of the ERBB receptors and their ligands in GC are not well established. METHODS: 
      We evaluated the expression levels of various ERBB receptor ligands (i.e., 
      heparin-binding epidermal growth factor-like growth factor [HBEGF], transforming 
      growth factor-alpha [TGFA], amphiregulin [AREG], epiregulin [EREG], epidermal growth 
      factor [EGF], and betacellulin [BTC]) and 3 ERBB family receptors (i.e., 
      epidermal growth factor receptor [EGFR], human EGFR2 [HER2], and ERBB3) in 313 
      cases of GC using immunohistochemistry, fluorescence in situ hybridization, and 
      mRNA in situ hybridization. RESULTS: A high expression of EGFR, HER2, and ERBB3 
      was observed in 30, 32, and 27 cases, respectively. A high expression of HBEGF, 
      TGFA, AREG, EREG, EGF, and BTC was observed in 91, 97, 151, 74, 26, and 37 cases, 
      respectively. A high expression of TGFA was associated with better survival, 
      while a high expression of BTC was associated with worse survival. These results 
      were confirmed using Cox proportional hazards analysis. HBEGF, TGFA, AREG, 
      tumor-node-metastasis classification, Lauren's classification, and ERBB3 were 
      significant survival parameters in multivariate analysis. CONCLUSION: Among the 
      ERBB family receptors and ligands examined, 3 ligands (i.e., TGFA, HBEGF, and 
      AREG) and ERBB3 had a prognostic impact.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Byeon, Sun-Ju
AU  - Byeon SJ
AD  - Department of Pathology, Seoul National University College of Medicine, Seoul, 
      Korea.
FAU - Lee, Hye Seung
AU  - Lee HS
FAU - Kim, Min-A
AU  - Kim MA
FAU - Lee, Byung Lan
AU  - Lee BL
FAU - Kim, Woo Ho
AU  - Kim WH
LA  - eng
PT  - Journal Article
DEP - 20170412
PL  - Switzerland
TA  - Pathobiology
JT  - Pathobiology : journal of immunopathology, molecular and cellular biology
JID - 9007504
RN  - 0 (Ligands)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (ERBB3 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-3)
SB  - IM
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Ligands
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
MH  - Receptor, ErbB-3/metabolism
MH  - Republic of Korea
MH  - *Signal Transduction
MH  - Stomach Neoplasms/*metabolism/mortality
MH  - Tissue Array Analysis
OTO - NOTNLM
OT  - Analysis
OT  - ErbB receptors
OT  - Gastric cancer
OT  - Ligands
EDAT- 2017/04/12 06:00
MHDA- 2018/01/23 06:00
CRDT- 2017/04/12 06:00
PHST- 2017/01/03 00:00 [received]
PHST- 2017/02/16 00:00 [accepted]
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2018/01/23 06:00 [medline]
PHST- 2017/04/12 06:00 [entrez]
AID - 000464250 [pii]
AID - 10.1159/000464250 [doi]
PST - ppublish
SO  - Pathobiology. 2017;84(4):210-217. doi: 10.1159/000464250. Epub 2017 Apr 12.